Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Mebeverine hydrochloride 135 mg Film-coated Tablets
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Mebeverine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for Mebeverine Hydrochloride 135 mg Film-coated Tablets contain the active ingredient mebeverine hydrochloride. This belongs to a group of medicines called antispasmodics. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Irritable bowel syndrome (IBS) is a very common condition which causes spasm and pain in the gut or intestine. The intestine is a long muscular tube which food passes down so it can be digested. If the intestine goes into spasm and squeezes too tightly, you get pain. The way this medicine works is by relieving the spasm, pain and other symptoms of IBS. The main symptoms of irritable bowel syndrome (IBS) include:
- stomach pain and spasm
- feeling bloated and having wind
- having diarrhoea (with or without constipation)
- small, hard, pellet-like or ribbon-like stools (faeces) These symptoms may vary from person to person.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. There is only limited information about the safety of Mebeverine Tablets for pregnant women. Your doctor may advise you to stop taking Mebeverine Tablets before you become pregnant or as soon as you know you are pregnant. Mebeverine Tablets should not be used during breast-feeding. Driving and using machines This medicine is not likely to affect you being able to drive or use any tools or machines. Mebeverine Tablets contain lactose and sodium Lactose- If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. Sodium- This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially 'sodium-free'.
How to take it
Mebeverine Tablets Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Children and adolescents: Mebeverine Tablets are not recommended for use in children and adolescents below 18 years of age.
This leaflet was last revised in December 2020.
If you take more Mebeverine Tablets than you should If you or someone else takes too many Mebeverine Tablets (an overdose), talk to a doctor or go to a hospital straight away. Take the medicine pack with you. If you forget to take Mebeverine Tablets If you forget to take a dose, take it as soon as you remember. However, if it is almost time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. If you stop taking Mebeverine Tablets Do not stop taking the tablets without talking to your doctor, even if you feel better. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects
Some people find that learning to relax can help to lessen their symptoms of IBS. You may find it helpful to set aside a few moments each day to relax and gently unwind.
These other effects are less serious. If they bother you talk to a pharmacist:
- Skin rash, red itchy skin.
Mebeverine Tablets with food and drink You can drink alcohol while you are taking Mebeverine Tablets. Other medicines and Mebeverine Tablets Mebeverine is not known to interact with other medicines but you should tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
The tablets are packaged in PVC/PVdC-Alu blister packs. Pack sizes: 7, 10, 12, 14, 15, 18, 20, 21, 28, 30, 56, 60, 84, 90 and 100 tablets. Not all pack sizes may be marketed.
Manufacturer Morningside Pharmaceuticals Ltd. 5 Pavilion Way Loughborough, LE11 5GW, UK
If you notice the following, stop taking the tablets and go to your doctor immediately, or your nearest hospital.
- Difficulty in breathing, swelling of the face, neck, tongue or throat (severe allergic reactions).
If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine.
What Mebeverine Tablets look like and contents of the pack Mebeverine Hydrochloride 135mg Film-coated Tablets are white to off-white, round film-coated tablets, 10 mm diameter, debossed with M135 on one side and plain on other side.
Adults (including the elderly):
- The recommended dose is one tablet three times a day.
- Do not take more than three tablets per day.
- The number of tablets you take may be lowered if your symptoms improve.
Your diet and lifestyle can also help treat IBS: How you restrict your diet depends on the way IBS affects you. If you find that certain foods bring on the symptoms, then it makes sense not to eat them. A high fibre diet may help, but ask your pharmacist for more information.
Warnings and precautions Talk to your doctor or pharmacist before taking Mebeverine Tablets if:
- you have developed new symptoms or your symptoms have become worse,
- you have liver or kidney problems.
The other ingredients are: Tablet core: lactose monohydrate, silicified microcrystalline cellulose, sodium starch glycolate (Type A), povidone, talc (E553b), and magnesium stearate. Tablet coating: poly (vinyl alcohol) – part hydrolyzed (E1203), talc (E553b), titanium dioxide (E171), glycerol monocaprylocaprate (type I), and sodium laurilsulfate.
Marketing Authorisation Holder Morningside Healthcare Ltd. Unit C, Harcourt Way Leicester, LE19 1WP, UK
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Do not take Mebeverine Tablets If you are allergic to mebeverine hydrochloride or any of the other ingredients of this medicine (listed in section 6).
What Mebeverine Tablets contain The active substance is mebeverine hydrochloride. Each film-coated tablet contains 135 mg mebeverine hydrochloride.
Try to take the tablet twenty minutes before a meal – some people find their symptoms to be strongest after they have eaten. Swallow the tablet whole with a glass of water. Do not chew the tablet.
Talk to your doctor if these symptoms do not improve after a while, if you develop new symptoms or you are concerned about your symptoms.
Possible side effects
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
How to store it
Mebeverine Tablets Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and carton after 'EXP'. The expiry date refers to the last day of that month. Do not store above 25°C. Store in the original package. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Contents of the pack and other information
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible
Frequently asked questions about Mebeverine hydrochloride 135 mg Film-coated Tablets
How do I take Mebeverine hydrochloride 135 mg Film-coated Tablets?
Mebeverine hydrochloride 135 mg Film-coated Tablets comes as tablet containing 135mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Mebeverine hydrochloride 135 mg Film-coated Tablets?
The active substance in Mebeverine hydrochloride 135 mg Film-coated Tablets is mebeverine hydrochloride.
Are there equivalent medicines to Mebeverine hydrochloride 135 mg Film-coated Tablets?
Medicines with the same active substance, strength and form include: Boots IBS Symptom Relief 135mg Tablets, Mebeverine 135mg film-coated tablets, Mebeverine hydrochloride 135mg film-coated tablets. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Mebeverine hydrochloride 135 mg Film-coated Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Mebeverine hydrochloride 135 mg Film-coated Tablets without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: mebeverine hydrochloride
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
For the symptomatic treatment of irritable bowel syndrome and other conditions usually included in this grouping, such as: chronic irritable colon, spastic constipation, mucous colitis, spastic colitis. Mebeverine is effectively used to treat the symptoms of these conditions, such as: colicky abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.
4.2. Posology and method of administration
Posology
Duration of use is not limited.
If one or more doses are missed, the patient should continue with the next dose as prescribed; the missed dose(s) should not be taken in addition to the regular dose.
Adults (including the elderly):
One tablet three times a day, preferably 20 minutes before meals. After a period of several weeks, when the desired effect has been obtained, the dosage may be gradually reduced.
Paediatric population:
Mebeverine hydrochloride 135 mg film-coated tablets are not recommended for use in children and adolescents below 18 years, due to insufficient data on safety and efficacy.
Special population:
No posology studies in elderly, renal and/or hepatic impaired patients have been performed. No specific risk for elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients.
Method of administration
For oral use.
The film-coated tablets should be swallowed with a sufficient amount of water (at least 100 ml water). Tablets should not be chewed because of the unpleasant taste.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4. Special warnings and precautions for use
Lactose
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption should not take this medicine.
Sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
4.5. Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed, except with alcohol. In vitro and in vivo studies in animals have demonstrated the absence of any interaction between mebeverine hydrochloride and ethanol.
4.6. Fertility, pregnancy and lactation
Pregnancy
There are no or limited amounts of data from the use of mebeverine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Mebeverine is not recommended during pregnancy.
Breast-feeding
It is unknown whether mebeverine or its metabolites are excreted in human milk. The excretion of mebeverine in milk has not been studied in animals. Mebeverine should not be used during breast-feeding.
Fertility
There are no clinical data on male or female fertility; however, animal studies do not indicate harmful effects of mebeverine (see section 5.3).
4.7. Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. The pharmacodynamic and pharmacokinetic profiles as well as postmarketing experience do not indicate any harmful effect of mebeverine on the ability to drive or to use machines.
4.8. Undesirable effects
The following adverse reactions have been reported spontaneously during postmarketing use. A precise frequency cannot be estimated from available data.
Allergic reactions mainly but not exclusively limited to the skin have been reported.
Immune system disorders:
Hypersensitivity (anaphylactic reactions)
Skin and subcutaneous tissue disorders:
Urticaria, angioedema, face oedema and exanthema.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Theoretically CNS excitability may occur in cases of overdose. In cases where mebeverine was taken in overdose, symptoms were either absent or mild and usually rapidly reversible. Observed symptoms of overdose were of a neurological and cardiovascular nature.
No specific antidote is known and symptomatic treatment is recommended.
Gastric lavage should only be considered in case of multiple intoxication or if discovered within about one hour. Absorption reducing measures are not necessary.
💬 Ask about this leaflet
Ask anything about Mebeverine hydrochloride 135 mg Film-coated Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.